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To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth factor
receptor monoclonal antibody matuzumab combined with epirubicin, cisplatin and capecitabine (ECX) in patients as first-line
treatment for advanced oesophagogastric cancer that express epidermal growth factor receptor (EGFR). This was a phase I dose
escalation study of matuzumab at 400 and 800mg weekly and 1200mg every 3 weeks combined with ECX (epirubicin 50mgm
 2,
cisplatin 60mgm
 2 on day 1 and capecitabine 1000mgm
 2 daily). Patients were treated until disease progression, unacceptable
toxicity or for a maximum of eight cycles. Twenty-one patients were treated with matuzumab at three different dose levels (DLs)
combined with ECX. The main dose-limiting toxicity (DLT) was grade 3 lethargy at 1200mg matuzumab every 3 weeks and thus
800mg matuzumab weekly was the maximum-tolerated dose (MTD). Other common toxicities included rash, nausea, stomatitis and
diarrhoea. Pharmacokinetic evaluation demonstrated that the coadministration of ECX did not alter the exposure of matuzumab.
Pharmacodynamic studies on skin biopsies demonstrated inhibition of the EGFR pathway. Objective response rates of 65% (95%
confidence interval (CI): 43–82), disease stabilisation of 25% (95% CI: 11–47) and a disease control rate (CRþPRþSD) of 90%
were achieved overall. The MTD of matuzumab in combination with ECX was 800mg weekly, and at this DL it was well-tolerated
and showed encouraging antitumour activity. At the doses evaluated in serial skin biopsies, matuzumab decreased phosphorylation of
EGFR and MAPK, and increased phosphorylation of STAT-3.
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Oesophagogastric (OG) cancer represents a major health burden
worldwide (Parkin, 2001). For patients with advanced disease
combination, chemotherapy has shown a survival benefit com-
pared to best supportive care (Murad et al, 1993; Pyrhonen et al,
1995).
ECF (epirubicin, cisplatin, infused 5FU) is the reference regimen
in the United Kingdom and other parts of Europe for advanced OG
cancer based on superior response rates, survival and global QOL
in several phase III studies (Webb et al, 1997; Waters et al, 1999;
Ross et al, 2002). Furthermore, a recent meta-analysis concluded
that the best survival results are achieved with regimens containing
anthracyclines, cisplatin and 5FU and among these ECF was the
most well-tolerated (Wagner et al, 2006).
Recently, the V325 study demonstrated a survival benefit
for TCF (docetaxel, cisplatin and 5FU) vs CF (cisplatin and
5FU) although TCF was associated with 480% grade 3 and 4
neutropaenia (Van Cutsem et al, 2006). The randomised phase III
trial REAL-2 evaluated four treatment arms ECF, EOF, ECX and
EOX (E, epirubicin; X, capecitabine; C, cisplatin; O, oxaliplatin; F,
5FU). Non-inferiority was demonstrated for capecitabine vs 5FU
and oxaliplatin vs cisplatin with acceptable toxicity for all
treatment arms (Cunningham et al, 2008).
Despite recent advances, the median overall survival with
combination chemotherapy is approximately 10–11 months, thus
newer treatment strategies are required. The epidermal growth
factor receptor (EGFR) has previously been identified as a novel
target for anticancer treatment. Epidermal growth factor receptor
activation leads to a cascade of signal transduction pathways
involved in cell proliferation, angiogenesis, metastasis and
invasion (Kim and Muller, 1999; Olayioye et al, 1999; Sako et al,
2000; Schlessinger, 2000). In oesophageal cancer, expression of
EGFR has been reported to be 80–90% (Itakura et al, 1994) and is
associated with poorer survival.
Matuzumab is a humanised antibody that competitively inhibits
natural ligand binding to the EGF receptor with abrogation of
EGFR downstream signalling. Matuzumab has also shown anti-
body-dependent cellular cytotoxicity in these models (Bier et al,
1998). Antitumour activity of matuzumab has been observed in
non-clinical xenograft models (Amendt et al, 2003; Burger et al,
2003).
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sIn a phase I study of matuzumab monotherapy in solid tumours,
grade 3 headache was identified as the main dose-limiting toxicity
(DLT) at 2000mg weekly, the maximum-tolerated dose (MTD) was
1600mg weekly and antitumour activity was seen in one heavily
pre-treated oesophageal cancer patient (Vanhoefer et al, 2004). In
recent phase I studies of chemotherapy plus matuzumab in lung
and pancreatic cancer (at doses ranging from 100 to 800mg
weekly), the MTD was not reached although one DLT of grade 4
neutropaenia was observed at matuzumab 800mg combined with
paclitaxel. Antitumour activity was reported and pharmaco-
dynamic data revealed blockade of the EGFR pathway (Graeven
et al, 2006; Kollmannsberger et al, 2006). Preliminary data of the
phase I study of PFL (cisplatin, leucovorin and 5FU) and
matuzumab (at doses of 400 or 800mg weekly) in advanced OG
cancer indicate good tolerability at the 400mg dose level (DL)
(Trarbach et al, 2005).
The primary objective of this phase I study was to determine the
MTD, recommended dose (RD), safety, tolerability, pharmaco-
kinetic and pharmacodynamic profile of matuzumab combined
with ECX in advanced OG tumours expressing EGFR.
PATIENTS AND METHODS
Study design
This phase I open label study was divided into two parts. The first
two cycles were designated as phase A, to determine the MTD,
pharmacokinetic and pharmacodynamic parameters. In phase B,
matuzumab plus ECX was continued on the DL selected in phase A
until disease progression, unacceptable toxicity or for a further
six cycles. Patients who did not complete phase A for any reason,
except unacceptable toxicities or progressive disease, were
replaced.
Patients
Eligibility requirements included histologically confirmed adeno-
carcinoma of the stomach or lower third of the oesophagus, locally
advanced, metastatic or recurrent disease, measurable disease
by computed tomography (CT), EGFR expression in tumour
tissue, normal cardiac function defined by left ventricular ejec-
tion fraction, Karnofsky performance status (KPS) X60%, life
expectancy 412 weeks, no prior chemotherapy at all, no radio-
therapy or major surgery within 4 weeks before the first study
treatment, adequate baseline bone marrow and liver function, a
glomerular filtration rate 460mlmin
 1, no severe uncontrolled
comorbidities and signed informed consent.
The study protocol was approved by the local ethics committee
and was carried out according to the Declaration of Helsinki and
good clinical practice guidelines. The subjects’ informed consent
was obtained before any study-related activities.
EGFR expression
Tumour material was obtained from the initial tumour resection or
diagnostic biopsy. Epidermal growth factor receptor expression
was determined by a central pathologist in representative paraffin-
embedded tumour blocks using EGFR pharmDx test kit (from
DakoCytomation KGaA, Darmstadt, Germany) as previously
reported. Tumours were considered positive if any membrane
staining was observed. Only patients with EGFR-positive tumours
were enrolled. All assessments were performed and reviewed
centrally.
Pre-treatment and evaluation
Pre-treatment evaluation consisted of medical history, physical
examination, full blood count (FBC), serum biochemistry, serum
tumour marker, urine analysis, CT scans of the chest abdomen
pelvis, multiple gated acquisition scan and chest X-ray. During
treatment, monitoring included clinical toxicities assessment, FBC,
serum biochemistry and physical examination weekly. Computed
tomography scans were performed at weeks 6 and 12 and at the
end of the treatment. Flectrocardiogram (ECG), KPS assessment
and FBC and biochemistry were repeated at the end of the
treatment.
Administration and dose escalation
Matuzumab was supplied by Merck (Germany) as a lyophilisate of
200mg per vial. Matuzumab was administered as a 1-h intravenous
infusion without premedication in 250ml of 0.9% normal saline
solution. ECX comprised of epirubicin 50mgm
 2 given as a 15-
min infusion, cisplatin 60mgm
 2 given as a 4-h infusion on day 1
and capecitabine 500mgm
 2 twice daily given continuously, each
cycle duration being 3 weeks. Pre-medication and hydration were
administered as described previously (Sumpter et al, 2005).
Initially, the study was planned with two DLs of matuzumab 400
and 800mg weekly combined with ECX. However, an amendment
was made to the protocol after pharmacodynamic data from a
phase I matuzumab monotherapy study revealed that 1200mg
three weekly was the target effective dose. This provided a strong
rationale for extending the dose regimen from weekly to a three-
weekly schedule (Tabernero et al, 2003). Thus two additional DLs
of matuzumab 1200 and 1600mg, administered every 3 weeks with
ECX, were included (Table 1).
No intrasubject dose escalation was performed. At each DL, six
patients were initially enrolled. If p1 of the patients experienced
a DLT during the first two cycles, the next cohort of patients
was treated at the subsequent DL. If X2 of 6 patients at one DL
experienced any DLT, additional patients were enrolled at the same
DL. The MTD and RD were defined as the DL at which not more
than one of six patients experienced a DLT.
Evaluation of toxicities and response
Toxicities were evaluated weekly and graded according to the
National Cancer Institute Common Toxicity Criteria (NCI-CTC;
version 2.0). The MTD was based on DLTs observed during the first
two cycles. Dose-limiting toxicity was defined as follows: an adverse
event related to matuzumab including any grade 3/4 non-haemato-
logical toxicities (excluding alopaecia, nausea, vomiting and skin
reactions), grade 4 nausea, vomiting and skin reactions and toxicity-
related discontinuation of treatment for more than 1 week.
Tumour response was measured by CT scans according to
RECIST criteria using unconfirmed responses (Therasse et al,
2000). Progression-free survival (PFS) was defined as the interval
between the date of administration of the first infusion and the
confirmation of progressive disease or death, depending on which
occurred first.
Pharmacokinetics
For pharmacokinetic analysis, blood samples were taken before
and 1, 2, 5, 48, 96, 168 and 336h after the start of the matuzumab
Table 1 Study design and dose escalation
Dose level Matuzumab absolute dose
a Planned no. of patients
1 400mg per week 6
2 800mg per week 6
3 1200mg per 3 weeks 6
4 1600mg per 3 weeks 6
ECX¼epirubicin, cisplatin and capecitabine.
aAdministered in combination with
fixed-dose ECX.
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sinfusion in weeks 1 and 4. Serum samples were obtained and
handled as previously described (Vanhoefer et al, 2004). Con-
centrations of matuzumab were measured in serum using a
validated ELISA. On the basis of the resulting concentrations, PK
parameters were calculated by compartmental and non-compart-
mental standard methods using the software package KINETICAt,
version 4.1.1.
Pharmacodynamics
Normal skin tissue biopsies from the upper arm at the posterior
surface were taken before the first cycle, after the second cycle and
fourth cycle. Tumour biopsies were taken by endoscopy as part of
the routine staging before the first cycle, at the end of the second
and fourth cycles. The percentage of cells staining positive for
proteins on skin and tumour biopsies were determined as
biological markers of the treatment. These pharmacodynamic
markers comprised phosphorylated EGFR (p-EGFR), phos-
phorylated p42/44 MAP kinase (p-MAPK), EGFR, Ki67, p27,
phosphorylated STAT3 (p-STAT3) and cytokeratin 1. In addition,
phosphorylated protein kinase B was measured in tumour biopsies
only. The samples were prepared and investigated as previously
described (Albanell et al, 2002).
RESULTS
Between 2002 and 2005, 45 patients underwent EGFR testing for
the study at the Royal Marsden Hospital, UK and 60% exhibited
positive EGFR expression by immunohistochemical analysis. In
total, 21 patients with EGFR-positive tumours received study
treatment (Table 1). Baseline patient characteristics are shown in
Table 2.
No DLT was observed in the initial cohort. At the 800mg
matuzumab DL, one patient experienced a DLT of grade 3
hypotension. One patient was replaced at each DL as per protocol.
At the next DL of matuzumab 1200mg every 3 weeks, 1 DLT of
grade 3 pancreatitis and 1 DLT of grade 3 abdominal pain were
reported; however, the DLT of grade 3 lethargy occurred in three of
six patients, indicating that the MTD was exceeded. Thus the main
DLT was grade 3 lethargy, and inconsistent with our previous
experience with ECX chemotherapy, therefore, one further patient
was entered at this DL. However, this patient experienced the same
DLT, thus four of seven patients experienced the main DLT of
grade 3 lethargy. Hence, the DL of 800mg matuzumab weekly
combined with ECX was defined as the MTD and the RD.
During phase B, the median number of cycles of treatment was
five for the first two cohorts and three for the 1200mg matuzumab
DL. Among the most frequent toxicities observed were diarrhoea,
nausea, vomiting and stomatitis, which can be associated with ECX
chemotherapy (Table 3). The most significant matuzumab-related
side effects (grades 1–4) across all DLs were lethargy and rash
affecting 11 and 13 patients, respectively.
One patient with a recurrent anastomotic OGJ tumour treated at
the first DL developed an oesophagobronchial fistula and died
subsequent to aspiration pneumonia. The patient had received one
dose of matuzumab (400mg per week) and ECX; this event was
deemed unrelated to study treatment.
Efficacy
Although efficacy was not a primary objective, 20 patients were
assessable for tumour response. Thirteen of 20 patients achieved a
Table 2 Patient demographics
Characteristic Total (N¼21) %
Gender
Male 16 76.2
Female 5 23.8
Age (years)
Median 59
Karnofsky performance status
60 1 4.8
70 2 9.5
80 5 23.8
90 13 61.9
Primary tumour location
Lower one-third of oesophagus 5 23.8
OGJ 7 33.3
Gastric 9 42.9
Adenocarcinoma 21 100
Stage (AJCC)
IIIb 1 5
IV 20 95
ECX¼epirubicin, cisplatin and capecitabine; OGJ¼oesophagogastric junction.
Table 3 NCI-CTC all grade toxicities
ECX+matuzumab 400mg
weekly N¼7
ECX+matuzumab 800mg
weekly N¼7
ECX+matuzumab 1200mg
every 3 weeks N¼7
Adverse
events
NCI-CTC grade NCI-CTC grade NCI-CTC grade Total (%)
Toxicity 1 234123412 3 4
Rash 1 200401023 0 0 1 3 61.9
Headache 0 000000010 0 0 1 4 . 8
Diarrhoea 5 000310021 2 0 1 4 66.7
Abdo pain 1 100102001 2 0 8 3 8
P P E 0120021000 0 0 6 28.6
Stomatitis 3 200220051 0 1 1 6 76.2
Nausea 3 210210022 3 0 1 6 7 6
Vomiting 3 210001024 1 0 1 4 66.7
Lethargy 1 101212101 6 C 01 6 7 6
Neutropaenia 0 0 1 0 3 1 1 2 4 12 57
Febrile neutropaenia 0 000000000 0 1 1 4 . 8
Thrombocytopaenia 0 010000000 0 0 1 4 . 8
ECX¼epirubicin, cisplatin and capecitabine; NCI-CTC¼National Cancer Institute Common Toxicity Criteria; C¼Main DLT.
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spartial response resulting in an overall objective response rate
(ORR) of 65% (95% confidence interval (CI): 43–82). Five patients
(25%) (95% CI: 11–47) demonstrated disease stabilisation and two
(10%) developed progressive disease. The ORR according to DL is
shown in Table 4.
One patient with a T3N1 gastric tumour was downstaged to
T2N0 on endoscopic ultrasound after five cycles of ECX plus
matuzumab (400mg per week) and underwent surgical resection
followed by post-operative ECX plus matuzumab.
The overall median time to disease progression was 5.2 months
(95% CI: 3.0–16.0).
Pharmacokinetic analysis parameters are shown in Table 5.
Maximum serum concentrations Cmax were achieved on average
1–2h after the end of the infusion. The mean values for Cmax for
all three DLs ranged between 154 and 442mgml
 1 in week 1 and
were dose proportional. The AUC results in the first week AUC
(0-168) were also approximately dose proportional.
The terminal elimination phase was best characterised in the
1200mg dose group where the concentration–time profile could
be assessed over a 3-week period after each matuzumab infusion.
Mean terminal elimination half-lives determined after weeks 1 and
4 were in the range of 8–9 days. At lower weekly dosing, only
apparent t1/2 were determined with values of 5–7 days. The mean
values for the volume of distribution were consistently small
(B4l) and dose independent. The mean trough values increased
over time towards the steady state (Figure 1). There was evidence
of accumulation at the 800mg weekly DL; there was no correlation
between the incidence of DLTs and Cmax and AUC.
Pharmacodynamics
Pharmacodynamic results were available from 18 subjects in total.
Skin biopsy data were consistent between patients at each DL
(Figure 2). Following the administration of matuzumab, the total
EGFR expression remained in the range of 80–100%. In contrast,
EGFR phosphorylation was inhibited and there was a similar
reduction in pMAPK for all investigated DLs. Increased levels of
p27 and p-STAT3 were detected. Baseline Ki67 decreased following
matuzumab treatment in all but one patient. Cytokeratin 1 levels in
skin biopsies generally increased during treatment although there
were decreased levels in two patients. The changes in these marker
proteins described were not dose dependent.
Tumour biopsy data were available for 15 pre-treatment biopsies
but limited for the treatment samples due to poor fixation of
tumour tissue. This reflects the difficulties in sampling tumour
tissue after the administration of chemotherapy. Thus it was not
possible to evaluate the changes observed during treatment in
tumour biopsies.
Further investigations were performed to evaluate any correla-
tion between the development of rash and PD changes particularly
in the skin biopsies. It was not possible to identify a clear
Table 4 Objective response to ECX plus matuzumab at all dose levels
400mg matuzumab 800mg matuzumab 1200mg matuzumab Total
Dose level weekly N¼7
a weekly N¼7 every 3 weeks N¼7 N¼21
a
Response n (%) n (%) n (%) n (%)
Partial response (PR) 4 (66.7 [30–90]) 3 (42.8 [16–75]) 6 (85.7 [49–97]) 13 (65 [43–82])
Stable disease (SD) 2 (33.3 [10–70]) 2 (28.6 [8–64]) 1 (14.3 [3–51]) 5 (25 [11–47])
Tumour growth control (PR+SD) 6 (100 [61–100]) 5 (71.4 [36–92]) 7 (100 [65–100]) 18 (90 [70–97])
Progressive disease (PD) 0 (0 [0–39]) 2 (28.6 [8–64]) 0 (0 [0–35]) 2 (10 [3–30])
ECX¼epirubicin, cisplatin and capecitabine.
aResponse data missing from one patient. The values inside square brackets denote 95% confidence interval.
Table 5 Pharmacokinetic parameters of matuzumab derived by non-compartmental analysis
Week 1 Week 4
400mg per week 800mg per week 1200mg per 3 weeks 400mg per week 800mg per week 1200mg per 3 wk
Cmax, mgml
 1 154 (44) 7 294 (89) 7 442 (108) 7 224 (54) 6 495 (166) 6 534 (125) 6
tmax, h 2.04 (1.05) 7 1.88 (1.45) 7 1.61 (0.55) 7 3.91 (1.81) 6 3.88 (1.88) 6 1.68 (1.63) 6
AUCt, mgml
 1h
 1 10717 (1553) 6 23347 (8748) 6 79189 (19217) 5 19674 (4720) 5 52797 (20448) 5 94868 (22029) 5
AUC0–N
a, mgml
 1h
 1 12721 (3519) 6 35406 (10593) 7 88066 (24277) 7 NA NA NA
t1/2, h 80.5 (15) 6 110.8 (36.2) 7 189.5 (23.2) 7 131.4 (31.1) 6 165 (35) 6 221.3 (70.8) 6
CL, h
 1 0.034 (0.0115) 6 0.0243 (0.0069) 7 0.0145 (0.0038) 7 0.0214 (0.0054) 5 0.0170 (0.0061) 5 0.0131 (0.0025) 5
V
b, l 3.64 (0.53) 6 3.76 (1.51) 7 3.83 (1.14) 7 3.92 (0.44) 5 3.43 (0.96) 5 4.64 (1.22) 5
aAUC0–N is not applicable (NA) for week 4.
bThe values reported are Vss for week 1 and VZ for week 4. The symbols not explained in the text are tmax, time of Cmax; AUCt/
AUC0 N, AUC within one dosing interval/from time 0 to infinity after single administration; CL, clearance; V (Vss/VZ), volume of distribution (at steady state/in the terminal
phase). Mean (±s.d.) is given, together with the number of underlying values in the adjacent column.
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Figure 1 Concentration–time courses of matuzumab in the dose
groups 400mg weekly (dashed line and circles), 800mg weekly (continuous
line and triangles) and 1200mg every 3 weeks (bold line and squares). The
mean concentrations (symbols) are fitted with a two-compartment model
per dose group.
ECX/matuzumab in advanced oesophagogastric cancer
S Rao et al
871
British Journal of Cancer (2008) 99(6), 868–874 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
scorrelation between the change of any PD marker protein in skin
or tumour biopsies during matuzumab therapy and the presence
of skin rash or response outcome.
DISCUSSION
This study has demonstrated that ECX combined with matuzumab
weekly at doses up to 800mg per week were generally well-
tolerated. At 1200mg of matuzumab three weekly, the MTD was
exceeded and the main DLT experienced by four of seven patients
was grade 3 lethargy. This occurred after the first infusion and
generally took several weeks to resolve completely. All four
patients were of KPS 90 before commencing treatment.
The interim analysis of the REAL-2 study reported 9% grade 3/4
lethargy for patients treated with ECX (Sumpter et al, 2005).
Asthenia has previously been reported with cetuximab (a chimeric
anti-EGFR antibody) in colorectal cancer (CRC). Abubakr et al
(2006) observed 25% asthenia (6% grade 3/4) in the phase III EPIC
study of irinotecan plus or minus cetuximab in 783 patients with
refractory CRC. Schrag et al (2005) described a magnesium-wasting
syndrome associated with severe fatigue-affecting patients with CRC
treated with cetuximab and irinotecan. They recommended that
serum magnesium levels be monitored for any patient with severe
asthenia following administration of cetuximab. In this study
(initiated before this publication), the lethargy observed did not
appear to be associated with serum hypomagnesaemia, although
magnesium was not routinely measured. Thus the mechanism of the
fatigue remains unknown but may be due to an interaction between
matuzumab at 1200mg three weekly and ECX chemotherapy.
No allergic reactions, other severe or unexpected adverse events
were observed. NCI-CTC grade 1/2 rash was observed in 61.9% of
patients in total, which is similar to that previously observed in a
phase I study of matuzumab monotherapy (Vanhoefer et al, 2004).
However, the incidence of rash appears lower than reported with
other anti-EGFR monoclonal antibodies including cetuximab or
panitumumab, which range between 80 and 90% for all grades
(Cunningham et al, 2004; Malik et al, 2005). The skin toxicity
associated with anti-EGFR antibodies is commonly described as an
acneiform rash but pathologically resembles an infectious
folliculitis (Lenz, 2006) and its pathophysiological mechanism
remains unclear.
The pharmacokinetic analyses demonstrated a dose-propor-
tional increase of AUC and Cmax for matuzumab with accumula-
tion suggesting linear pharmacokinetics within the dose range
tested. There was no correlation between the incidence of the DLT
of lethargy and Cmax and AUC in the 1200mg cohort. In addition,
when comparing the Cmax and AUC0–168 of matuzumab plus ECX
to a previous matuzumab monotherapy study (Vanhoefer et al,
2004), it was found that the matuzumab exposure was similar. This
suggests that the coadministration of ECX chemotherapy did not
influence the pharmacokinetics of matuzumab.
The PD results obtained from the skin samples were as expected
and total EGFR expression was not altered; there was a decrease in
p-EGFR, p-MAPK and Ki67, whereas p27 and p-STAT3 increased
following the administration of matuzumab. Thus, overall, there
was abrogation of EGFR downstream signalling and there was no
dose–response relationship. Therefore, there is inhibition of the
EGFR network at doses of matuzumab below the MTD. Similar
findings have been reported utilising varying schedules of
matuzumab (Tabernero et al, 2003; Vanhoefer et al, 2004). It is
not possible in this study to comment on the use of skin as a
surrogate for tumour, given the limitations of the tumour biopsies.
There has been much controversy surrounding EGFR expression
by immunohistochemistry and the use of anti-EGFR therapy. In
this study, all patients were EGFR-positive according to immuno-
histochemistry; however, there was no apparent correlation
between the degree of EGFR inhibition and objective response.
Although efficacy was not a primary objective, only patients with
measurable disease were included in the study. The unconfirmed
ORR with the combination of ECX plus matuzumab was 65 with
25% disease stabilisation, that is a disease control rate (CR,
PRþSD) of 90%, and the median PFS was 5.2 months. The
unconfirmed ORR for ECX in the REAL-2 study was 46.4%
(Cunningham et al, 2008); hence there may be a synergistic or
additive effect between matuzumab and ECX although no conclu-
sions can be drawn from these data and further investigation is
required in a randomised study. The median time to progression in
this study was 5.2 months and thus shorter than that reported for all
treatment arms in REAL-2 (Cunningham et al,2 0 0 8 ) .T h i sm a y
partly be accounted for by the 1200mg matuzumab cohort who
received only five median cycles of treatment and the dose delays
incurred before restarting chemotherapy by those patients who
experienced the main DLT of grade 3 lethargy.
Several phase I and II studies of EGFR tyrosine kinase inhibitors
as immunotherapy in previously treated OG cancers have been
reported with response rates ranging from 2.85 to 12% (Ferry et al,
2004; Van Groeningen and Giaccone, 2004; Janmaat et al, 2006). A
phase II study of cetuximab combined with FOLFIRI in untreated
gastric and OGJ cancers achieved an ORR of 44.1% (95% CI 27.5–
60.9%) (Pinto et al, 2007). Janmaat et al (2006) identified female
gender, squamous histology and high EGFR expression to be
associated with improved outcome following the administration of
gefitinib in patients with advanced OG cancer. A study of erlotinib
demonstrated activity in OGJ tumours but no objective responses in
gastric cancers (Dragovich et al, 2006). In this trial, the inclusion
criteria stipulated adenocarcinoma and the responses to ECX and
matuzumab were observed in oesophageal, OGJ and gastric tumours.
In conclusion, this trial has demonstrated that the MTD of
matuzumab in combination with ECX was 800mg weekly and at
this DL it was generally well tolerated. Grade 3 lethargy was the
main DLT at 1200mg three weekly and the mechanism for this
remains unclear. The combination regimen was associated with
clinically meaningful tumour response and stabilisation and the
PD markers in skin reflected inhibition of the EGFR signalling at
all DLs. Thus a randomised national multicentre phase II trial of
ECX with or without the addition of matuzumab at 800mg weekly
in advanced untreated OG cancer has been conducted.
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